In this issue

INDIAN BIOPHARMA HITS RS 25,000 CRORE RIDING 15% GROWTH WAVE

The Indian Biopharma Industry, with over 300 companies, is growing at the rate of 15 per cent, which is 3 per cent more than the previous year’s 12 per cent. This growth was largely driven by over 20 per cent growth rate recorded by 8 of the top 20 companies in the biopharma space. As a result, the Indian Biopharma Industry has crossed the Rs 25,000 crore mark for the year 2019-20 over the previous year’s figure of Rs 22,124 crore. In 2017-18 the industry recorded a revenue of Rs 18,290 crore. The Indian Biopharma industry, comprising hormones, insulin, blood products and vaccines recorded a sales revenue of Rs 25,442 crore for the year 2019-20.

For Feedback, please email us at : communications@mmactiv.com

Govt launches SARS-CoV-2 genomic consortium to monitor viral mutations

The government has launched the Indian SARS-CoV-2 Genomic Consortia (INSACOG), comprising 10 labs namely DBT-NIBMG Kalyani, DBT-ILS Bhubaneswar, ICMRNIV Pune, DBT-NCCS Pune, CSIR-CCMB Hyderabad, DBT-CDFD Hyderabad, DBT-InSTEM/ NCBS Bengaluru, NIMHANS Bengaluru, CSIR-IGIB Delhi, and NCDC Delhi.

1 min

Govt works towards AYUSH export promotion council

The Ministry of Commerce and Industry and the Ministry of AYUSH have decided to work together to set up an Export Promotion Council to boost AYUSH exports.

1 min

Piramal Pharma invests $32M to expand API facility in US

Mumbai based Piramal Pharma Limited’s Pharma Solutions business, a leading contract development and manufacturing organization (CDMO), has announced plans to expand its facility in Michigan in the US with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).

1 min

Korea conducts typhoid vaccine study in Nepal

Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK Bioscience based in South Korea, has met the primary endpoints in a Pase III study in Nepal.

1 min

WHO announces updates on systematic screening for TB

World Health Organization (WHO) has announced a number of updates to its forthcoming guidance on the systematic screening of tuberculosis (TB) disease.

1 min

9 Trends Of New Post-Covid Era

As the world wakes up to the new post-COVID reality, the vaccine industry is entering a new paradigm that is one in which vaccines are perceived as effective medical interventions, which will have wider acceptance in the society, and which need to be supported.

5 mins

INDIAN BIOPHARMA HITS RS 25,000 CRORE RIDING 15% GROWTH WAVE

The Indian Biopharma Industry, with over 300 companies, is growing at the rate of 15 per cent, which is 3 per cent more than the previous year’s 12 per cent.

10+ mins

GAVI nominates Dr Harsh Vardhan as India representative

Dr Harsh Vardhan, Union Minister, Health and Family Welfare has been nominated by the Global Alliance for Vaccines and Immunisation (GAVI) as a member of the GAVI Board. He will be representing the South-East Area Regional Office (SEARO)/ Western Pacific Regional Office (WPRO) constituency on the GAVI Board from January 1, 2021 until December 31, 2023.

1 min

BARC develops indigenous Ruthenium 106 plaque to treat eye cancer

Dr Jitendra Singh, Union Minister of State (Independent Charge) Development of North Eastern Region (DoNER), MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space has lauded the Bhabha Atomic Research Centre (BARC) in Mumbai for developing eye cancer therapy in the form of the first indigenous Ruthenium 106 plaque for treatment of ocular tumours.

1 min

CSIR reveals anti-viral benefits of chlorhexidine mouthwash

A preliminary laboratory based research conducted by researchers at Panjab University in collaboration with CSIR-Institute of Microbial Technology (IMTECH) has revealed that one of the most routinely used mouth rinses, Chlorhexidine, has proven to be effective against SARS-CoV-2.

1 min

Read all stories from Bio Spectrum

Bio Spectrum Magazine Description:

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.